Pancreatic cancer is notoriously aggressive and difficult to treat but a recent FDA ruling may help put odds more in patients’ favor. Last week the FDA approved Lynparza for use as a maintenance treatment for certain pancreatic cancer patients. The drug was found to significantly expand the amount of time patients lived without disease progression.
Chances are you’ve already heard of Lynparza. The PARP inhibitor is currently approved in various countries for the maintenance treatment of certain types of ovarian cancer and breast cancer. Now, the drug can add pancreatic cancer to its repertoire. Lynparza works by preventing cells that have been destroyed by chemotherapy from repairing themselves. As a result, cancer progression is slowed.